Relevance. Platelet activation and platelet aggregation are central processes in the pathophysiology of coronary heart disease and thrombosis. The relationship between cardiovascular morbidity and mortality varies with the presence of other concomitant cardiovascular risk factors.
Objective. To determine the state of platelet hemostasis in patients with essential hypertension (HT), with concomitant non-alcoholic fatty liver disease (NAFLD).
Materials and methods. 152 patients were examined: 72 men and 80 women. Three groups were identified: I - 46 patients with stage II HT without concomitant NAFLD, II - 54 patients with NAFLD without HT, group III - 52 patients with HT and concomitant NAFLD. A study of total platelet count, mean platelet volume (MPV), platelet distribution width (PDW), platelet count (PCT) and spontaneous platelet aggregation was performed.
Results. The level of mean platelet volume (MPV) in both groups of patients with hepatic steatosis exceeded control values equally - by 6%, both in patients with NAFLD (p<0.001) and in NAFLD with concomitant hypertension (p<0.01). In patients of the NAFLD group and hypertension, the relative width of the platelet distribution by volume (PDW) had high values - 2% (p<0.05) higher than in the control cohort, and 2.4% (p<0.05) than in patients with isolated HT. An increase in the degree of spontaneous aggregation in patients of all surveyed groups compared to controls. So in patients with HT II stage. spontaneous aggregation increased 2.2 times (p<0.001), while in both groups of patients with hepatic steatosis, the increase in spontaneous platelet activity was twice as high: in patients with NAFLD - 4.3 times (p<0.001), in patients with HT II stage. and concomitant NAFLD - 4.1 times (p<0.001).
Conclusion. NAFLD is accompanied by an increased in MPV, the size of which correlates with their functional activity. In patients with isolated NAFLD, a statistically significant increase in spontaneous platelet aggregation is also observed, which allows considering NAFLD as one of the risk factors for thrombophilic changes in the primary hemostasis.
Younossi Z.M., Koenig A.B., Abdelati D., Fazel Y., Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. DOI: 10.1002/hep.28431
Fotbolcu H., Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease.World journal of gastroenterology. 2016;22(16):4079-90. DOI: 10.3748/wjg.v22.i16.4079
Publisher site: https://www.wjgnet.com/1007-9327/full/v22/i16/4079.htm
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837427/
Oikonomou D., Georgiopoulos G., Katsi V., Kourek C., Tsioufis C., Alexopoulou A., Koutli E., Tousoulis D. Non-alcoholic fatty liver disease and hypertension. European Journal of Gastroenterology & Hepatology. 2018;30(9):979-85. DOI: 10.1097/MEG.0000000000001191
Papapanagiotou A., Daskalakis G., Siasos G., Gargalionis A., Papavassiliou A.G. The role of platelets in cardiovascular disease: molecular mechanisms. Current pharmaceutical design. 2016;22(29):4493-505. DOI: 10.2174/1381612822666160607064118
Publisher site: https://www.eurekaselect.com/143022/article
Panke C.L., Tovo C.V., Villela-Nogueira C.A. et al. Evaluation of thrombocytopenia in patients with non-alcoholic fatty liver disease without cirrhosis. Annals of Hepatology. 2020;19(1):88-91. DOI: 10.1016/j.aohep.2019.05.011.
Liu F. Zhou H., Cao L. et al. Risk of reduced platelet counts in patients with nonalcoholic fatty liver disease (NAFLD): a prospective cohort study. Lipids in Health and Disease. 2018; 17(1):221. DOI: 10.1186/s12944-018-0865-7
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145189/
Abeles R.D., Mullish B.H., Forlano R. et al. Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume. Alimentary Pharmacology & Therapeutics. 2019;49(8):1077-85. DOI: 10.1111/apt.15192
Publisher site: https://onlinelibrary.wiley.com/doi/full/10.1111/apt.15192
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519040/
Ranucci M., Aloisio T., Di Dedda U., La Rovere M.T., De Arroyabe B.M.L., Baryshnikova E. Platelet reactivity in overweight and obese patients undergoing cardiac surgery. Platelets. 2019;30(5):608-14. DOI: 10.1080/09537104.2018.1492108
Medvedev I.N., Skoryatina I.A. [Aggregation properties of blood cells and vascular control over them in patients with arterial hypertension and dyslipidemia]. Russian journal of Cardiology. 2015;4(120):18-22. [in Russian] DOI: 10.15829/1560-4071-2015-4-18-22
Publisher site: https://russjcardiol.elpub.ru/jour/article/view/277/0
Zaccardi F., Rocca B., Pitocco D., Tanese L., Rizzi A., Ghirlanda G. Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta-analysis. Diabetes/Metabolism Research and Reviews. 2015;31(4):402-10. DOI: 10.1002/dmrr.2625
Publisher site: https://onlinelibrary.wiley.com/doi/abs/10.1002/dmrr.2625
This work is licensed under a Creative Commons Attribution 4.0 International License.